Alkermes (ALKS) Free Cash Flow Growth (3y) (2013 - 2026)
Alkermes (ALKS) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.30 Bn | 39.65 Bn | 2.15 Bn | 14.41% |
| 3 | Zoetis | 31.45 Bn | 29.77 Bn | 1.05 Bn | 216.31% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | 4.08% |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | 49.44% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -10.40% |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | -9.38% |
| 8 | Elanco Animal Health | 11.70 Bn | 11.17 Bn | 798.00 Mn | 134.18% |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Alkermes | 8.11 Bn | 7.46 Bn | 397.90 Mn | -12.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.71% |
| Mar 31, 2026 | -82.02% |
| Dec 31, 2025 | 175.62% |
| Sep 30, 2025 | 119.43% |
| Jun 30, 2025 | 136.23% |
| Mar 31, 2025 | 85.54% |
| Dec 31, 2024 | 100.65% |
| Sep 30, 2024 | -2.02% |
| Jun 30, 2024 | 73.71% |
| Mar 31, 2024 | 30.85% |
| Dec 31, 2023 | 13.37% |
| Sep 30, 2023 | 16.59% |
| Jun 30, 2023 | 150.55% |
| Mar 31, 2023 | 22.32% |
| Dec 31, 2022 | -42.43% |
| Sep 30, 2022 | -41.83% |
| Jun 30, 2022 | 32.04% |
| Mar 31, 2022 | 127.22% |
| Dec 31, 2021 | -19.54% |
| Sep 30, 2021 | 65.95% |